Integra LifeSciences stock gains 1.50 percent as margins improve

Integra LifeSciences stock rose 1.50 percent to USD 15.76 on Nasdaq on September 24, 2026 at 3:08 p.m. ET, giving the medical device company a market capitalization of USD 1,225,951,344. The move comes as investors weigh improving profitability against refinancing and remediation work.

Margins improve in Q2

Integra reported Q2 2026 revenue of USD 418.76 million and adjusted EPS of USD 0.56, compared with USD 0.48 consensus. According to MarketBeat on September 18, 2026, the quarterly EPS beat consensus by USD 0.08, while revenue exceeded estimates by USD 1.22 million.

The latest quarterly statement also shows a clear profitability contrast. Finance data for Q2 2026 put GAAP revenue at USD 418.761 million, operating profit at USD 19.285 million and net income at USD 4.482 million, versus a net loss of USD 4.617 million in Q1 2026.

Cash flow meets refinancing

A September 8, 2026 Form 8-K presentation gives the longer-term picture. Stock Titan reports LTM Q2 2026 revenue of USD 1.648 billion, up 1.6 percent year over year, and adjusted EBITDA of USD 337 million, up 11.8 percent. The adjusted EBITDA margin was 20.5 percent, while operating cash flow reached USD 85 million.

The balance sheet remains central to the investment case. The same September 8 presentation puts net leverage at 4.1x compliance adjusted EBITDA, down from 4.5x in fiscal year 2025, while free cash flow recovered to USD 26 million from negative USD 31 million in fiscal year 2025.

Analyst target stays above price

MarketBeat lists an average Reduce rating from eight analysts and an average 12-month price target of USD 18.86 as of September 18, 2026. That target is USD 3.10 above the Nasdaq price of USD 15.76, a gap of 19.7 percent that leaves execution and debt reduction as the key valuation tests.

Stock remains below yearly high

Integra LifeSciences stock was trading at USD 15.76 on Nasdaq on September 24, 2026 at 3:08 p.m. ET. Its 52-week range was USD 8.70 to USD 20.49, placing the share price USD 4.73 below the yearly high.